Laurus Labs Ltd
LAURUSLABSLaurus Labs Ltd
LAURUSLABSPrice Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
HighShowing good signs of profitability & efficiency
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
---|---|---|
152.60 | 5.95 | 0.18% |
Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
---|---|---|
— | — | — |
Forecast & Ratings
Detailed Forecastfrom 13 analysts
Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Laurus Labs Private Ltd is a research and development pharmaceutical company which manufactures active pharmaceutical ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. It also manufactures APIs in oncology and other therapeutic areas.
Investor Presentation
View olderPeers
Compare with peersSun Pharmaceutical Industries Ltd
Cipla Ltd
Zydus Lifesciences Ltd
Dr Reddy's Laboratories Ltd
Torrent Pharmaceuticals Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
All values in ₹
All values in ₹
Revenue Forecast
All values in ₹ Thousand cr.
All values in ₹ Thousand cr.
Earnings Per Share Forecast
All values in ₹
All values in ₹
Income
Balance Sheet
Cash Flow
Income Statement
Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Total Revenue | 1,781.94 | 1,937.03 | 2,085.36 | 2,308.07 | 2,837.64 | 4,837.17 | 4,950.87 | 6,046.55 | 5,067.17 | 5,067.17 | ||||||||||
Raw Materials | 1,033.24 | 1,031.67 | 1,088.41 | 1,267.63 | 1,629.55 | 2,455.20 | 2,414.94 | 2,752.28 | 2,533.30 | 4,263.33 | ||||||||||
Power & Fuel Cost | 57.96 | 66.27 | 94.21 | 109.37 | 136.77 | 157.75 | 204.47 | 324.10 | 338.15 | |||||||||||
Employee Cost | 175.46 | 204.73 | 238.14 | 276.33 | 320.77 | 397.04 | 469.55 | 557.43 | 614.85 | |||||||||||
Selling & Administrative Expenses | 67.97 | 92.25 | 96.07 | 140.99 | 189.38 | 239.88 | 276.15 | 291.01 | 335.07 | |||||||||||
Operating & Other expenses | 80.75 | 102.10 | 126.03 | 141.61 | -9.30 | 12.96 | 148.03 | 523.54 | 441.96 | |||||||||||
EBITDA | 366.56 | 440.01 | 442.50 | 372.14 | 570.47 | 1,574.34 | 1,437.73 | 1,598.19 | 803.84 | 803.84 | ||||||||||
Depreciation/Amortization | 86.41 | 105.98 | 125.45 | 164.19 | 187.27 | 205.07 | 251.49 | 324.08 | 384.58 | 384.58 | ||||||||||
PBIT | 280.15 | 334.03 | 317.05 | 207.95 | 383.20 | 1,369.27 | 1,186.24 | 1,274.11 | 419.26 | 419.26 | ||||||||||
Interest & Other Items | 111.11 | 99.90 | 79.64 | 88.19 | 89.59 | 68.16 | 102.39 | 165.17 | 182.90 | 182.90 | ||||||||||
PBT | 169.04 | 234.13 | 237.41 | 119.76 | 293.61 | 1,301.11 | 1,083.85 | 1,108.94 | 236.36 | 236.36 | ||||||||||
Taxes & Other Items | 35.30 | 43.86 | 69.81 | 25.99 | 38.34 | 317.53 | 256.33 | 318.83 | 75.81 | 75.81 | ||||||||||
Net Income | 133.74 | 190.27 | 167.60 | 93.77 | 255.27 | 983.58 | 827.52 | 790.11 | 160.55 | 160.55 | ||||||||||
EPS | 0.86 | 1.81 | 3.17 | 1.77 | 4.79 | 18.36 | 15.41 | 14.69 | 2.98 | 2.98 | ||||||||||
DPS | 0.10 | 0.30 | 0.30 | 0.30 | 0.50 | 2.00 | 2.00 | 2.00 | 0.80 | 1.60 | ||||||||||
Payout ratio | 0.12 | 0.17 | 0.09 | 0.17 | 0.10 | 0.11 | 0.13 | 0.14 | 0.27 | 0.54 |
Company Updates
Peers & Comparison
Health CarePharmaceuticals
Valuation
Technical
Forecast
Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
---|---|---|---|
Laurus Labs Ltd | 152.60 | 5.95 | 0.18% |
Sun Pharmaceutical Industries Ltd | 39.30 | 6.34 | 0.86% |
Cipla Ltd | 29.01 | 5.04 | 0.88% |
Zydus Lifesciences Ltd | 30.31 | 5.94 | 0.26% |
Price Comparison
Compare LAURUSLABS with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Total Retail Holding
In last 3 months, retail holding in the company has almost stayed constant
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Jun 2023
Sep 2023
Dec 2023
Mar 2024
Shareholding History
Mutual Funds Holding Trend
Increased Mutual Fund Holding
In last 3 months, mutual fund holding of the company has increased by 1.10%
Top 5 Mutual Funds holding Laurus Labs Ltd
Funds (Top 5) | The rupee value of the stock held by the fund divided by the stock’s market cap Market-cap held | Percentage of the fund’s portfolio invested in the stock Weight | Change in the portfolio weight of the stock over the last 3 months 3M holding change | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months Portfolio rank(3M change) |
---|---|---|---|---|
Mirae Asset Large & Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.7764% | Percentage of the fund’s portfolio invested in the stock 1.23% | Change in the portfolio weight of the stock over the last 3 months 0.98% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 63/104 (+26) |
Mirae Asset ELSS Tax Saver Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 1.5720% | Percentage of the fund’s portfolio invested in the stock 1.70% | Change in the portfolio weight of the stock over the last 3 months 0.78% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 51/91 (+10) |
Mirae Asset Midcap Fund - Growth - Direct Plan Growth | The rupee value of the stock held by the fund divided by the stock’s market cap 0.8854% | Percentage of the fund’s portfolio invested in the stock 1.41% | Change in the portfolio weight of the stock over the last 3 months 0.26% | The rank of the stock in the fund’s portfolio based on its weight in the portfolio along with the change in the rank over the last 3 months 55/82 (-2) |
Compare 3-month MF holding change on Screener
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Trend In Dividends
LAURUSLABS has shown inconsistent dividend trend over the last 5 years
Dividend Yield
Current dividend yield is 0.18%. An investment of ₹1,000 in the stock is expected to generate dividend of ₹1.83 every year
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateMay 8, 2024
Dividend/Share
₹0.40
Ex DateEx Date
May 8, 2024
Cash Dividend
Ex DateEx DateNov 2, 2023
Dividend/Share
₹0.40
Ex DateEx Date
Nov 2, 2023
Cash Dividend
Ex DateEx DateMay 10, 2023
Dividend/Share
₹1.20
Ex DateEx Date
May 10, 2023
Cash Dividend
Ex DateEx DateNov 3, 2022
Dividend/Share
₹0.80
Ex DateEx Date
Nov 3, 2022
Cash Dividend
Ex DateEx DateMay 10, 2022
Dividend/Share
₹1.20
Ex DateEx Date
May 10, 2022
News & Opinions
Laurus Labs edges lower after CARE Ratings downgrades rating outlook to ‘negative’
2 weeks ago•Business Standard
Brokerage Views: Citi On Ambuja Cements, Laurus Labs And More
3 weeks ago•Bloomberg Quint
Laurus Labs Ltd spurts 0.12%, gains for fifth straight session
3 weeks ago•Business Standard
Laurus Labs Strategically Focused On Talent Acquisition And Programme Advancement, Says CEO Chava
2 months ago•Bloomberg Quint
News Video
Laurus Labs Q4 Results: CEO Satyanarayana Chava Dissects Numbers | Talking Point | NDTV Profit
2 months ago•NDTV Profit
News Video
Laurus Labs: Commercial Opportunity In NCE Projects, Prioritising Capex In High Value Segments
2 months ago•ET NOW
Laurus Labs Q4 Results Review - Product Mix, Reduced Operating Leverage Hurt Profitability: Motilal Oswal
2 months ago•Bloomberg Quint
Higher than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of 17.03%, vs industry avg of 9%
Increasing Market Share
Over the last 5 years, market share increased from 1.04% to 1.42%
Lower than Industry Net Income
Over the last 5 years, net income has grown at a yearly rate of 11.35%, vs industry avg of 15.09%